Payment overview · 2025
General Payments
$2,896.15
23 reported records · 13 companies
Healthcare provider profile · identity verified
Aleksandr Batikov, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1629058706
Verified facts
What the public records show
CMS Open Payments records show Aleksandr Batikov, MD received $2,896.15 in general payments during 2025 across 23 reported records.
ABBVIE INC. accounted for 24.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Linzess, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $715.65 | 24.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $375.30 | 13.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $339.74 | 11.7% | 3 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $255.99 | 8.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $245.39 | 8.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $128.32 | 4.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $125.00 | 4.3% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $125.00 | 4.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $125.00 | 4.3% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $121.58 | 4.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $120.10 | 4.2% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$109.54 | 3.8% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $109.54 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,896.15 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $375.30 | 3 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $255.99 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $253.38 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $245.39 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $219.08 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $154.19 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $153.44 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $128.32 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $124.32 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $121.58 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $120.66 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $120.10 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $109.54 | 1 | 2025 |
Source payment records
|
|||||
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $109.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 33 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 83 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 38 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
33 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
138 | 17 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 472 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 384 | 47 |
| Atorvastatin Calcium | Atorvastatin Calcium | 335 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 312 | 43 |
| Eliquis | Apixaban | 306 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 288 | 48 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 272 | 86 |
| Furosemide | Furosemide | 253 | 49 |
| Losartan Potassium | Losartan Potassium | 219 | 31 |
| Metformin Hcl | Metformin Hcl | 182 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 181 | 29 |
| Famotidine | Famotidine | 178 | 35 |
| Omeprazole | Omeprazole | 173 | 26 |
| Synthroid | Levothyroxine Sodium | 138 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 22 |
| Carvedilol | Carvedilol | 123 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 19 |
| Silver Sulfadiazine | Silver Sulfadiazine | 114 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 108 | 17 |
| Trazodone Hcl | Trazodone Hcl | 108 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 103 | 25 |
| Januvia | Sitagliptin Phosphate | 101 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 100 | 11 |
| Sertraline Hcl | Sertraline Hcl | 98 | 12 |
| Memantine Hcl | Memantine Hcl | 96 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 14 |
| Memantine Hcl Er | Memantine Hcl | 95 | 18 |
| Gabapentin | Gabapentin | 89 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 89 | 51 |
| Jardiance | Empagliflozin | 83 | 11 |
| Ranolazine Er | Ranolazine | 79 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 77 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 76 | 52 |
| Dexlansoprazole Dr | Dexlansoprazole | 74 | 13 |
| Mirtazapine | Mirtazapine | 74 | suppressed |
| Lisinopril | Lisinopril | 72 | 14 |
| Xarelto | Rivaroxaban | 72 | suppressed |
| Potassium Chloride | Potassium Chloride | 70 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 65 | 22 |
| Ssd | Silver Sulfadiazine | 64 | 31 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 63 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 60 | suppressed |
| Nystatin | Nystatin | 58 | 23 |
| Finasteride | Finasteride | 56 | suppressed |
| Telmisartan | Telmisartan | 56 | suppressed |
| Tradjenta | Linagliptin | 56 | suppressed |
| Atenolol | Atenolol | 55 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 54 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 53 | suppressed |
| Loperamide | Loperamide Hcl | 51 | 23 |
| Torsemide | Torsemide | 50 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | suppressed |
| Glimepiride | Glimepiride | 49 | suppressed |
| Lidocaine | Lidocaine | 49 | 24 |
| Simvastatin | Simvastatin | 48 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 46 | suppressed |
| Mupirocin | Mupirocin | 46 | 25 |
| Vascepa | Icosapent Ethyl | 46 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 32 |
| Zenpep | Lipase/Protease/Amylase | 44 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | suppressed |
| Entresto | Sacubitril/Valsartan | 41 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 40 | 12 |
| Allopurinol | Allopurinol | 40 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 40 | suppressed |
| Linzess | Linaclotide | 38 | 12 |
| Spironolactone | Spironolactone | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 15 |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Creon | Lipase/Protease/Amylase | 33 | 19 |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 13 |
| Digoxin | Digoxin | 32 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 32 | suppressed |
| Nyamyc | Nystatin | 32 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 31 | 11 |
| Dutasteride | Dutasteride | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 14 |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Nystop | Nystatin | 26 | 15 |
| Bumetanide | Bumetanide | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Proctozone-Hc | Hydrocortisone | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Belsomra | Suvorexant | 21 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Procto-Med Hc | Hydrocortisone | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Edarbi | Azilsartan Medoxomil | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,896.15 · 23 records | ABBVIE INC. | AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, CREON, CREXONT, EVENITY, IBSRELA, JARDIANCE, LINZESS, LYBALVI, QULIPTA, UBRELVY, XCOPRI, XIFAXAN, ZENPEP, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error